Individualising therapy for older adults with diabetes mellitus

Drugs and Aging

Volumn 24, Issue 10, 2007, Pages 851-863

  Cayea, Danelle ^a   Boyd, Cynthia ^a   Durso, Samuel C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INCRETIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; LIPID; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOLBUTAMIDE; TROGLITAZONE;

BODY BURDEN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DRUG EXCRETION; DRUG METABOLISM; FLATULENCE; GASTROINTESTINAL SYMPTOM; GERIATRIC DISORDER; GLYCEMIC CONTROL; HEALTH HAZARD; HEALTH STATUS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INDIVIDUALIZATION; INSULIN TREATMENT; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIVER TOXICITY; MICROANGIOPATHY; MONOTHERAPY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT; SMOKING CESSATION; TREATMENT PLANNING; WEIGHT GAIN;

EID: 35048887519     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724100-00005     Document Type: Review

References (86)

1. Sinclair A. Clinical guidelines for type 2 diabetes mellitus. European Diabetes Working Party for Older People, 2001-2004 [online]. Available from URL: http://www.eugms.org/documents/clinicalguidelinediabetes.pdf [Accessed 2007 Aug 23]
2. Park E, Durso SC, Confessore GJ. A case study of educational practices for the aging global population. Lifelong Educ Lib 2006; 6: 67-79
3. Landefeld CS, Callahan CM, Woolard N. General internal medicine and geriatrics: building a foundation to improve the training of general internists in the care of older adults. Ann Intern Med 2003; 139 (7): 609-14
4. National Diabetes Information Clearinghouse. National diabetes statistics [online]. Available from URL: http://diabetes.niddk.nih.gov/dm/pubs/statistics/ index.htm [Accessed 2007 Aug 23]
5. Durso SC. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA 2006; 295 (16): 1935-40
6. Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51 (5 Suppl. Guidelines): S265-80
7. Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000; 320 (7246): 1380-4
8. Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000; 320 (7231): 341-6
9. Arora NK, McHorney CA. Patient preferences for medical decision making: who really wants to participate? Med Care 2000; 38 (3): 335-41
10. Say RE, Thomson R. The importance of patient preferences in treatment decisions: challenges for doctors. BMJ 2003; 327 (7414): 542-5
11. Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA 2004; 291 (19): 2359-66
12. Vijan S, Hayward RA, Ronis DL, et al. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 2005; 20 (5): 479-82
13. Huang ES, Gorawara-Bhat R, Chin MH. Self-reported goals of older patients with type 2 diabetes mellitus. J Am Geriatr Soc 2005; 53 (2): 306-11
14. Maddigan SL, Feeny DH, Majumdar SR, et al. Understanding the determinants of health for people with type 2 diabetes. Am J Public Health 2006; 96 (9): 1649-55
15. Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res 2005; 14 (5): 1311-20
16. Deaton C, Kimble LP, Veledar E, et al. The synergistic effect of heart disease and diabetes on self-management, symptoms, and health status. Heart Lung 2006; 35 (5): 315-23
17. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162 (20): 2269-76
18. Niefeld MR, Braunstein JB, Wu AW, et al. Preventable hospitalization among elderly Medicare beneficiaries with type 2 diabetes. Diabetes Care 2003; 26 (5): 1344-9
19. Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood) 2001; 20 (6): 233-41
20. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006; 29 (3): 725-31
21. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294 (6): 716-24
22. Standards of medical care in diabetes: 2006. Diabetes Care 2006; 29 Suppl. 1: 4-42
23. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004; 61 (10): 1042-9
24. Harman JS, Edlund MJ, Fortney JC, et al. The influence of comorbid chronic medical conditions on the adequacy of de-pression care for older Americans. J Am Geriatr Soc 2005; 53 (12): 2178-83
25. Fenton JJ, Von Korff M, Lin EH, et al. Quality of preventive care for diabetes: effects of visit frequency and competing demands. Ann Fam Med 2006; 4 (1): 32-9
26. Wray LA, Ofstedal MB, Langa KM, et al. The effect of diabetes on disability in middle-aged and older adults. J Gerontol A Biol Sci Med Sci 2005; 60 (9): 1206-11
27. Volpato S, Blaum C, Resnick J, et al. Comorbidities and impairments explaining the association between diabetes and lower extremity disability: the Women's Health and Aging Study. Diabetes Care 2002; 25 (4): 678-83
28. Blaum CS, Ofstedal MB, Langa KM, et al. Functional status and health outcomes in older Americans with diabetes mellitus. J Am Geriatr Soc 2003; 51 (6): 745-53
29. Volpato S, Ferrucci L, Blaum C, et al. Progression of lower-extremity disability in older women with diabetes: the Women's Health and Aging Study. Diabetes Care 2003; 26 (1): 70-5
30. Covinsky KE, Hilton J, Lindquist K, et al. Development and validation of an index to predict activity of daily living dependence in community-dwelling elders. Med Care 2006; 44 (2): 149-57
31. Maty SC, Fried LP, Volpato S, et al. Patterns of disability related to diabetes mellitus in older women. J Gerontol A Biol Sci Med Sci 2004; 59 (2): 148-53
32. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154 (7): 635-41
33. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61 (5): 661-6
34. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999; 52 (5): 971-5
35. Feil D, Weinreb J, Sultzer D. Psychiatric disorders and psychotropic medication use in elderly persons with diabetes. Ann Long Term Care 2006; 14 (7): 39-47
36. Brown JS, Vittinghoff E, Lin F, et al. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002. Diabetes Care 2006; 29 (6): 1307-12
37. Volpato S, Leveille SG, Blaum C, et al. Risk factors for falls in older disabled women with diabetes: the Women's Health and Aging Study. J Gerontol A Biol Sci Med Sci 2005; 60 (12): 1539-45
38. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002; 324 (7353): 1577-80
39. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285 (21): 2750-6
40. Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006; 295 (7): 801-8
41. Harris R, Donahue K, Rathore SS, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003; 138 (3): 215-29
42. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138 (7): 593-602
43. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140 (8): 650-8
44. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29 (7): 1478-85
45. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353 (3): 238-48
46. Tinetti ME. Clinical practice: preventing falls in elderly persons. N Engl J Med 2003; 348 (1): 42-9
47. Tinetti ME, Doucette J, Claus E, et al. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc 1995; 43 (11): 1214-21
48. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994; 331 (13): 821-7
49. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16 (5): 468-74
50. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 837-53
51. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; (1): CD002967
52. Black J, Cefalu CA, Durso SC, et al. Diabetes mellitus: oral antidiabetic agents, insulin, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and calcium channel blockers. In: Geriatric pharmaceutical care guidelines: a clinical and cost reference tool for use in geriatric care. Covington (KY): Omnicare, 2005: 185-204
53. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137 (1): 25-33
54. Nisbet JC, Sturtevant JM, Prins JB. Metformin and serious adverse effects. Med J Aust 2004; 180 (2): 53-4
55. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003; 326 (7379): 4-5
56. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50 (6): 735-41
57. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157 (15): 1681-6
58. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33 (4): 278-85
59. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005; 28 (7): 601-31
60. Greco D, Angileri G. Drug-induced severe hypoglycaemia in type 2 diabetic patients aged 80 years or older. Diabetes Nutr Metab 2004; 17 (1): 23-6
61. Physicians' desk reference (2004). 58th ed. Montvale (NJ): Thomson PDR, 2004: 718-20, 742-3, 2603-4
62. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complicat 2004; 18 (1): 60-8
63. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44 (7): 751-5
64. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17 (6): 467-73
65. US FDA. Code of federal regulations. Title 21, Volume 5. Subpart E: Requirements for specific new drugs or devices. Sec. 310.517: labeling for oral hypoglycemic drugs of the sulfonylurea class [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFR-Search.cfm?fr=310. 517 [Accessed 2007 23 Aug]
66. Haas L. Management of diabetes mellitus medications in the nursing home. Drugs Aging 2005; 22 (3): 209-18
67. Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006; 55 (5 Suppl. 1): S16-9
68. Del Prato S, Heine RJ, Keilson L. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care 2003; 26 (7): 2075-80
69. Papa G, Fedele V, Rizzo MR. Safety of type 2 diabetes treatment with epaglinide compared with glibenclamide in elderly people. Diabetes Care 2006; 29: 1918-20
70. Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67 (1): 7-15
71. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Comparative effectiveness review No. 8 prepared by Johns Hopkins Evidence-based Practice Center under contract No. 209-02-0018. Rockville (MD). Agency for Healthcare Research and Quality, 2007 Jul [online]. Available from URL: http://effectivehealthcare.ahrq.gov/repFiles/OralFullReport.pdf [Accessed 2007 Aug 23]
72. Abramowicz M, Zuccotti G. Drugs for diabetes. Treat Guidel Med Lett 2005 Aug; 3 (36): 57-62
73. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27 (1): 256-63
74. US FDA. GlaxoSmithKline letter [online]. Available from URL: http://www.fda.gov/medwatch/safety/2006/Avandia_DHCPletter.pdf [Accessed 2006 Nov 21]
75. Beebe K, Patel J. Rosiglitazone is effective and well-tolerated in patients ≥65 years with type 2 diabetes [abstract]. Diabetes 1999; 42 (S1): A111
76. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366 (9493): 1279-89
77. Isley WL. Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. ACP J Club 2006; 144 (2): 34
78. Willms B, Rugge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 751-66
79. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98 (5): 443-51
80. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7 (1): 73-82
81. Inhaled insulin (Exubera). Med Lett Drugs Ther 2006; 48 (1239): 57-8
82. DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28 (8): 1922-8
83. Quattrin T, Bélanger A, Bohannon NJ, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-7
84. Rosenstock J, Cappelleri JC, Bolinder B, et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 2013-8
85. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 2005; 47 (1210): 45-6
86. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60 (11): 1454-70